



Marksans Pharma Ltd.

January 27, 2026

BSE Limited

Corporate Relation Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400001
Scrip Code: 524404

National Stock Exchange of India Limited

Listing Department
Exchange Plaza, C-1, Block - G
Bandra-Kurla Complex
Bandra (East), Mumbai - 400051
Symbol: MARKSANS

Sub.: Intimation regarding incorporation of two new wholly owned subsidiary companies.

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI LODR Regulations, this is to inform you that Marksans Pharma Limited has formed and incorporated the following two new wholly owned subsidiary companies:

1. Marksans Pharma (Europe) Limited in Ireland.
2. Marksans (Canada) Inc. in Canada.

The relevant details as required under SEBI LODR Regulations are enclosed as Annexure – A.

Thanking you.

Yours faithfully
For **Marksans Pharma Limited**

Harshavardhan Panigrahi
Company Secretary

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,
Andheri (W), Mumbai - 400 053 Tel.: +91 22 4001 2000

E-mail: companysecretary@marksanspharma.com

www.marksanspharma.com



Marksans Pharma Ltd.

Annexure A

Sr. No.	Particulars	Marksans Pharma (Europe) Limited	Marksans (Canada) Inc.
1	Name of the target entity, details in brief such as size, turnover etc.;	The name of the wholly owned subsidiary is Marksans Pharma (Europe) Limited, incorporated in Ireland. Size/Turnover: Not applicable being a newly incorporated company.	The name of the wholly owned subsidiary is Marksans (Canada) Inc., incorporated in Canada. Size/Turnover: Not applicable being a newly incorporated company.
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	Not Applicable	Not Applicable
3	Industry to which the entity being acquired belongs;	Pharmaceutical	Pharmaceutical
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The wholly owned subsidiary has been incorporated in Ireland for the purpose of carrying on the business of pharmaceutical products.	The wholly owned subsidiary has been incorporated in Canada for the purpose of carrying on the business of pharmaceutical products.
5	Brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable	Not Applicable
6	Indicative time period for completion of the acquisition;	Not Applicable	Not Applicable
7	Consideration - whether cash consideration or share swap or any other form and details of the same;	Not Applicable	Not Applicable
8	Cost of acquisition and/or the price at which the shares are acquired;	Not Applicable	Not Applicable
9	Percentage of shareholding / control acquired and / or number of shares acquired;	The Company is a wholly owned subsidiary.	The Company is a wholly owned subsidiary.
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	History and Turnover: Not Applicable, being a newly incorporated company.	History and Turnover: Not Applicable, being a newly incorporated company.

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 Tel.: +91 22 4001 2000

E-mail: companysecretary@marksanspharma.com

www.marksanspharma.com